Human herpesvirus-6 (HHV-6) is the etiological agent in most patients with a primary exanthem subitum infection, and it is often reactivated in immunosuppressed patients following hematopoietic stem cell transplantation (HSCT). 1, 2 We report a female infant with ALL who developed primary HHV-6 infection during the early phase of allogeneic cord blood stem cell transplantation (CBSCT). The patient developed vesiculobullous eruptions that were indistinguishable from the skin lesions of acute GVHD. She was diagnosed with primary HHV-6 infection by virus isolation from the peripheral blood and detection of HHV-6 using the PCR. She was successfully treated with ganciclovir.
A 2-month-old female infant was admitted with a 2-day history of fever. She was born at 39 weeks' gestation and weighed 3.0 kg. Her family history was unremarkable; there was no evidence of consanguinity. On admission, physical examination revealed conjunctival pallor and hepatosplenomegaly. Laboratory findings were: WBC count 26.8 Â 10 9 per liter (L1 blasts, 95%), hemoglobin 6.1 g per 100 ml, platelet count 323 Â 10 9 per liter, C-reactive protein 11 mg per 100 ml, lactate dehydrogenase 626 IU/l (normal range: 119-229) and uric acid 6.8 mg per 100 ml (normal range: 2.3-7.0). She was diagnosed with ALL based on her BM specimen that had 85.5% CD10À, CD19 þ and HLA-DR þ lymphoblastic cells. Karyotype analysis of the blast cells showed 46, XX, t(4;11)(q21;q23). Mixed-lineage leukemia (MLL) gene rearrangement was confirmed on FISH and Southern blotting. MLL/AF4 fusion gene mRNA was detected using the reverse transcriptase-PCR.
The patient was given induction chemotherapy shortly after diagnosis, and complete remission was confirmed. After two courses of consolidation chemotherapy, CBSCT from an unrelated donor was performed. The conditioning regimen consisted of 4 mg/kg per day of targeted oral BU on days À8 to À5, 60 mg/kg of etoposide on day À4 and 60 mg/kg per day of CY on days À3 to À2. GVHD prophylaxis consisted of the continuous infusion of tacrolimus 0.02 mg/kg per day from day À1 and shortterm MTX, 10 mg /m 2 per day, on days þ 1, þ 3 and þ 6. G-CSF was administered from day þ 5. She received 20 mg/kg per day of acyclovir and weekly CMV hyperimmune globulin to prevent herpes virus and CMV infection, respectively. The cord blood donor was female, and her blood type was identical to that of the recipient. With respect to HLA disparity, one locus was mismatched serologically, and four alleles were mismatched genotypically in the GVHD direction (patient: A1101/2402, B1501/ 1507, Cw0303/0401 and DRB1 0403/0406; donor: A1101/ 1101, B1501/1501, Cw0303/0401 and DRB1 0405/0405). On day 0, 9.2 Â 10 7 per kg of mononuclear cells (1.34 Â 10 5 per kg of CD34 þ cells) were infused. Figure 1 shows the copy number of HHV-6 after HSCT. On day þ 14, 317 000 copies per ml (whole blood) of HHV-6 genomic DNA were detected from PBMCs on quantitative PCR. In spite of the absence of any clinical symptoms, ganciclovir was administered at a dose of 10 mg/kg per day from day þ 15. Neutrophil engraftment was achieved on day þ 16. Skin exanthema and vesiculobullous eruptions, which were indistinguishable from those seen in acute GVHD, suddenly appeared on the upper limbs, face and anterior chest wall on day þ 20. A skin biopsy specimen showed acantholysis with intraepidermal vesicular dermatitis. Although there was no sign of inclusion cells, small numbers of HHV-6-positive keratinocytes were observed in the immunostained section. In contrast, typical findings suggesting acute GVHD, such as apoptosis and intradermal lymphocytosis, were not observed. The histological diagnosis was herpetiform dermatitis (Figure 2 ). HHV-6 genomic DNA (3200 copies per ml) was detected from the fluid contents of the bullous lesion. The patient was diagnosed as having HHV-6-associated dermatitis and kept under observation without systemic steroid therapy. The skin symptoms gradually subsided within 2 weeks. HHV-6 virus was isolated from PBMCs. Patient's PBMCs were cocultured with cord blood mononuclear cells in culture medium. Viruses were identified primarily by morphologic changes in cultured cells (that is, characteristics of pleomorphic, balloon-like large cells). Virus isolation was confirmed by immunofluorescence staining with an HHV-6 monoclonal antibody (OHV-3; provided by T Okuno, Department of Microbiology, Hyogo College of Medicine, Hyogo, Japan). As this monoclonal antibody is variant B specific, all isolates that showed a positive reaction were considered to be HHV-6 variant B. The HHV-6 IgG antibody titer was 1:32 on days þ 14, þ 29 and þ 70. On day þ 21, chimerism analysis of a BM specimen showed 100% donor chimerism, and the patient remained in complete remission 2 years after CBSCT. Sashihara 2 and Tomonari 3 reported a high incidence of HHV-6 infection with high viral loads in CBSCT recipients, but their reports were based on HHV-6 reactivation in adult patients. As this patient had no history of exanthem subitum, her HHV-6 infection was considered to be a primary infection. The patient's HHV-6 antibody titer did not change before and after infection. A low HHV-6 IgG antibody level was detected before the appearance of the skin rash, which was inconsistent with primary infection. The low HHV-6 IgG antibody level may have been due to prophylactic administration of gammaglobulin or maternal antibody transfer.
The patient's vesiculobullous eruptions mimicked acute skin GVHD. Routine viral surveillance using PCR once a week enabled us to precisely diagnose her as having a primary HHV-6 infection, thereby avoiding harmful systemic steroid therapy. The efficacy of antiviral therapy for HHV-6 has not been confirmed in clinical trials. In vitro data have shown that ganciclovir is effective for HHV-6 type B, but HHV-6 type A is partially resistant to ganciclovir. 4 The patient became afebrile after ganciclovir was given, and the HHV-6 viral load rapidly decreased and became negative on day 70. Ganciclovir therapy was thought to be effective in this patient.
HHV-6 reactivation following HSCT causes fever, myelosuppression, interstitial pneumonitis, encephalitis, skin rash, and, rarely, vesiculobullous eruptions. [4] [5] [6] [7] Infantile HSCT recipients may suffer from a primary HHV-6 infection and develop severe skin lesions similar to acute GVHD, as in our patient. Regular surveillance for HHV-6 after HSCT should be mandatory in infant patients who receive CBSCT. (b) Human herpesvirus-6 (HHV-6) immunostaining. Skin biopsy showed the herpetiform dermatitis with bullous change. There were small numbers of lymphocytes infiltration in the interface area. However, no evidence of viral inclusion cells were observed, HHV-6 immunostaining could demonstrate very small number of positive keratinocyte (arrow).
